Login

Cart

Your cart is empty
Back to Knowledge Vault

Section 2 of 6

Therapeutic Generations

Every approved GLP-1 medication — from the body's own hormone to today's dual-action injectables. Mechanisms, efficacy data, and safety profiles explained in both scientific and plain language.

0
Endogenous Hormone

GLP-1 (7-37)

The Native Hormone

Your body's natural appetite controller and blood sugar assistant — released when you eat, cleared in minutes. Every GLP-1 medication is designed to mimic this.

2–5m
Half-life
60%
Postprandial insulin
Learn more
Generation 0 — Endogenous Hormone

GLP-1 (7-37)

The Native Hormone · Half-life: 2–5 minutes

Scientific Mechanism

GLP-1 (7-37) is a naturally occurring peptide hormone secreted by intestinal L-cells. It potentiates glucose-dependent insulin secretion (approximately 60% of postprandial insulin release), suppresses glucagon, slows gastric emptying, and promotes satiety through hypothalamic and brainstem GLP-1 receptor activation. Rapidly degraded by DPP-4 and NEP 24.11.

In Plain Language

GLP-1 is your body's natural appetite controller and blood sugar assistant. It's released when you eat to signal your pancreas to release insulin at the right time, help you feel full, and slow how quickly food leaves your stomach. Every GLP-1 medication is designed to mimic what this hormone does — but last much longer.

References
  • Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007
  • GLP-1 receptor: mechanisms and advances. Nature Signal Transduction. 2024
1
Injectable · Gen 1

Exenatide

Byetta / Bydureon

The first GLP-1 medication — originally discovered in Gila monster venom. Established cardiovascular safety but has been largely superseded by newer agents.

2–3kg
Weight loss
9%
MACE reduction (NS)
Full profile
Generation 1 — First GLP-1 RA

Exenatide

Byetta (twice-daily) / Bydureon (once-weekly) · Half-life: 2.4 hours

Scientific Mechanism

Derived from exendin-4, a peptide isolated from Gila monster venom. Shares 53% amino acid homology with human GLP-1 but resists DPP-4 degradation. Stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces food intake.

In Plain Language

Exenatide was the first injectable GLP-1 therapy — discovered in Gila monster venom. It works like your body's natural appetite hormone but lasts longer. Byetta requires twice-daily shots; Bydureon improved convenience to once-weekly.

Key Efficacy Data

A1C reductions of 0.8–1.4% with modest weight loss of 2–3 kg. EXSCEL CVOT (n=14,752): non-significant 9% MACE reduction (HR 0.91, 95% CI 0.83–1.00, p=0.06) — establishing cardiovascular safety but not superiority.

Safety

GI adverse events (nausea/vomiting in 20–40%); pancreatitis warning examined by FDA; injection site reactions with Bydureon.

References
  • Holman RR et al. EXSCEL. NEJM. 2017. PMID: 28912141
  • Eng J. Exendin peptides. Mount Sinai J Med. 1992
2
Injectable · Gen 2

Liraglutide

Victoza / Saxenda

97% identical to human GLP-1, modified with a fatty-acid anchor to last all day. First GLP-1 to prove cardiovascular superiority in the landmark LEADER trial.

~8%
Weight loss
13%
MACE reduction
Full profile
Generation 2 — Modified GLP-1 Analog

Liraglutide

Victoza (1.8 mg/day) / Saxenda (3.0 mg/day) · Half-life: ~13 hours

Scientific Mechanism

97% amino acid homology to native GLP-1, modified with a C16 palmitic acid side chain enabling albumin binding. This extends the half-life approximately 50-fold compared to native GLP-1.

In Plain Language

A daily injection nearly identical to your natural GLP-1 hormone but modified with a tiny fatty-acid "anchor" that makes it stick to blood proteins and last all day instead of a few minutes.

Key Efficacy Data

LEADER (n=9,340; 3.8 years): 13% MACE reduction (HR 0.87, p=0.01). Weight loss: 4–6 kg mean; A1C reduction: 0.8–1.6%. Saxenda trials: ~8% weight loss at 56 weeks in obesity.

Safety

GI events (nausea in 30–40%, transient); pancreatitis warning; MTC risk in animal studies (contraindicated with MTC/MEN2 history).

References
  • Marso SP et al. LEADER. NEJM. 2016. PMID: 27295427
3
Injectable & Oral · Gen 3

Semaglutide

Ozempic / Wegovy / Rybelsus

The most widely used GLP-1 medication — once-weekly injection or daily pill. First to prove cardiovascular benefit in obesity without diabetes.

15–21%
Weight loss
20%
MACE reduction
Full profile
Generation 3 — Advanced GLP-1 Analog

Semaglutide

Ozempic (0.5–2.0 mg weekly) / Wegovy (2.4 mg weekly) / Rybelsus (oral) · Half-life: ~7 days

Scientific Mechanism

94% homology to native GLP-1, modified at position 8 (Ala→Aib) for DPP-4 resistance and acylated with a C18 fatty diacid for extended albumin binding (~99% bound). Rybelsus uses SNAC permeation enhancer for oral absorption.

In Plain Language

The most widely used GLP-1 medication — a once-weekly injection (Ozempic/Wegovy) or daily pill (Rybelsus) that provides steady, week-long appetite control. An enhanced version of your body's natural hormone engineered to last dramatically longer.

Key Efficacy Data

STEP 1 (n=1,961; 68 weeks): 14.9% mean weight loss vs. 2.4% placebo. STEP UP (Phase 3b; n=1,407; 72 weeks): semaglutide 7.2 mg produced 20.7% weight loss; 33.2% achieved ≥25%. SELECT (n=17,604): 20% MACE reduction (HR 0.80, p<0.001) — first CV benefit in obesity without diabetes. SUSTAIN-6 (n=3,297; T2D): 26% MACE reduction.

Safety

GI events (nausea, vomiting, diarrhea, constipation); pancreatitis warning; MTC contraindication; retinopathy concerns in poorly controlled diabetes.

References
  • Wilding JPH et al. STEP 1. NEJM. 2021. PMID: 33567185
  • Wharton S et al. STEP UP. Lancet Diabetes Endocrinol. 2025
  • Lincoff AM et al. SELECT. NEJM. 2023. PMID: 37952131
  • Marso SP et al. SUSTAIN-6. NEJM. 2016. PMID: 27633186
4
Dual Agonist · Gen 4

Tirzepatide

Mounjaro / Zepbound

First-in-class dual GLP-1/GIP agonist — like getting two medications in one shot. The most powerful approved therapy for both blood sugar and weight.

20–23%
Weight loss
2.3%
A1C reduction
Full profile
Generation 4 — First Dual GLP-1/GIP Agonist

Tirzepatide

Mounjaro (2.5–15 mg weekly) / Zepbound (2.5–15 mg weekly) · Half-life: ~5 days

Scientific Mechanism

First dual GIP and GLP-1 receptor agonist. GIP enhances glucose-dependent insulin secretion and has direct adipose tissue effects, while GLP-1 targets postprandial glucose and central satiety. The dual mechanism produces complementary and additive metabolic effects.

In Plain Language

A dual-action weekly injection that targets two appetite and blood sugar hormones simultaneously — like getting two medications in one shot. This combination makes it the most powerful approved therapy for both blood sugar control and weight loss.

Key Efficacy Data

SURMOUNT-1 (n=2,539; 72 weeks): 22.5% weight loss at 15 mg; 57% achieved ≥20%. SURPASS-2 (head-to-head vs. semaglutide): superior A1C (−2.38% vs. −1.93%) and weight loss (−12.6 kg vs. −10.0 kg). SURPASS-CVOT (n=13,165; 4 years): noninferiority to dulaglutide for MACE; superiority for expanded endpoints including revascularization (HR 0.84, p<0.001).

Safety

GI events (60–70%, mostly mild-moderate, transient); pancreatitis warning; MTC contraindication; injection site reactions.

References
  • Jastreboff AM et al. SURMOUNT-1. NEJM. 2022. PMID: 35658024
  • Nicholls SJ et al. SURPASS-CVOT. NEJM. 2025. PMID: 41406444

At a Glance

Head-to-Head Comparison

Metric Exenatide (Gen 1) Liraglutide (Gen 2) Semaglutide (Gen 3) Tirzepatide (Gen 4)
Max Weight Loss 2–3 kg 4–8 kg (~8%) 15–21% 20–23%
A1C Reduction 0.8–1.4% 0.8–1.6% 1.5–2.0% 1.9–2.3%
Dosing BID / Weekly Daily Weekly (inj) / Daily (oral) Weekly
MACE Reduction 9% (NS) 13% 20–26% Noninferior to dulaglutide
Key CVOT EXSCEL LEADER SELECT / SUSTAIN-6 SURPASS-CVOT

Data from pivotal trials. Individual results vary. This comparison is educational — treatment decisions should be made with a healthcare provider.

Continue Exploring

Four generations of innovation — and the next one is already in trials.

The Pipeline Radar section covers experimental drugs that may define the next generation: oral pills, triple agonists, muscle-preserving combinations, and monthly dosing.

Back to Knowledge Vault

Next Section

Pipeline Radar

Previous Section

Clinical Realities

Daily Nutritional Support

Learn About GLPrelief